All In Biotech

Drug Trial Radar · NCT06082167

Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

A Phase 2/3, Randomized, Double-Blind, Controlled Study of Zanzalintinib (XL092) in Combination With Pembrolizumab vs Pembrolizumab in First-Line Treatment of Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Last checked: Nov 20, 2026Latest source record: Aug 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 600 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

600

Planned (sponsor's estimate)

Start

Jun 7, 2024

Primary completion

Aug 2028

Study completion Mar 2029

Sponsor

Lead sponsor
ExelixisIndustry
Sponsor type
Industry
Collaborators
Merck Sharp & Dohme LLC
First posted
Oct 13, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, randomized, double-blind, controlled Phase 2/3 trial of zanzalintinib in combination with pembrolizumab versus zanzalintinib-matched placebo in combination with pembrolizumab in subjects with programmed death-ligand 1 (PD-L1) positive recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) incurable by local therapies who have not received prior systemic therapy for recurrent or metastatic disease.

Conditions

  • Head and Neck Squamous Cell Carcinoma

Interventions

  • ZanzalintinibDrug

    Specified doses on specified days

  • Zanzalintinib-matched PlaceboDrug

    Specified doses on specified days

  • PembrolizumabBiological

    Specified doses on specified days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-Free Survival (PFS) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) by Blinded Independent Central Review (BICR)Time frame: Approximately 33 months after the first subject is randomized
  2. Overall Survival (OS)Time frame: Approximately 50 months after the first subject is randomized

Locations

168 sites in 26 countries. Site status is shown where the registry gives one.

  • Exelixis Clinical Site #2

    Fullerton, California

  • Exelixis Clinical Site #1

    Orange City, Florida

  • Exelixis Clinical Site #163

    Tampa, Florida

  • Exelixis Clinical Site #123

    Athens, Georgia

  • Exelixis Clinical Site #82

    Atlanta, Georgia

  • Exelixis Clinical Site #19

    Chicago, Illinois

  • Exelixis Clinical Site #62

    Des Moines, Iowa

  • Exelixis Clinical Site #100

    Iowa City, Iowa

  • Exelixis Clinical Site #4

    St Louis, Missouri

  • Exelixis Clinical Site #148

    Lebanon, New Hampshire

  • Exelixis Clinical Site #158

    Camden, New Jersey

  • Exelixis Clinical Site #3

    Shirley, New York

  • Exelixis Clinical Site #95

    Durham, North Carolina

  • Exelixis Clinical Site #117

    Wilson, North Carolina

  • Exelixis Clinical Site #43

    Roanoke, Virginia

  • Exelixis Clinical Site #91

    Buenos Aires, Argentina

  • Exelixis Clinical Site # 47

    Ciudad Autonoma de Buenos Aire, Argentina

  • Exelixis Clinical Site #53

    Ciudad Autonoma de Buenos Aire, Argentina

  • Exelixis Clinical Site #93

    Córdoba, Argentina

  • Exelixis Clinical Site #64

    Córdoba, Argentina

  • Exelixis Clinical Site #157

    Pergamino, Argentina

  • Exelixis Clinical Site #92

    Santa Fe, Argentina

  • Exelixis Clinical Site #73

    Rosario, Santa Fe Province, Argentina

  • Exelixis Clinical Site # 46

    Adelaide, Australia

  • Exelixis Clinical Site #154

    Bedford Park, Australia

  • Exelixis Clinical Site #137

    Camperdown, Australia

  • Exelixis Clinical Site #39

    Murdoch, Australia

  • Exelixis Clinical Site #57

    Port Macquarie, New South Wales, Australia

  • Exelixis Clinical Site #156

    Linz, Austria

  • Exelixis Clinical Site #42

    Salzburg, Austria

  • Exelixis Clinical Site #166

    Vienna, Austria

  • Exelixis Clinical Site #22

    Brussels, Belgium

  • Exelixis Clinical Site #106

    Charleroi, Belgium

  • Exelixis Clinical Site #14

    Libramont, Belgium

  • Exelixis Clinical Site #37

    Sint-Niklaas, Belgium

  • Exelixis Clinical Site #116

    Barretos, Brazil

  • Exelixis Clinical Site #75

    Curitiba, Brazil

  • Exelixis Clinical Site #101

    Curitiba, Brazil

  • Exelixis Clinical Site #97

    Porto Alegre, Brazil

  • Exelixis Clinical Site #102

    Recife, Brazil

Showing 40 of 168 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.